Company profile / KYMR

Kymera Therapeutics, Inc.

Clinaptis stanceCautious
ConvictionMedium
Ticker
KYMR
Exchange
NASDAQ
Coverage
Standard profile
Updated
Oct 30, 2026
Immunology / Targeted Protein Degradation

Clinical-stage company developing oral protein degraders, with an emphasis on immunology. Lead asset KT-621 is a wholly owned, once-daily oral degrader of STAT6, a transcription factor downstream of IL-4 and IL-13 signaling, the pathway Dupixent targets. It is in development for atopic dermatitis (AD), asthma and potentially other type 2 inflammatory diseases. The open-label Phase 1b BroADen study (22 adults, 28 days) showed median STAT6 degradation of 98% in blood and 94% in skin, with a 63% mean EASI improvement and no serious adverse events or conjunctivitis reported. The randomized, placebo-controlled Phase 2b BROADEN2 study (about 200 adolescents and adults, 16 weeks) has completed its last patient visit, with data guided by year-end 2026. The pipeline also includes the wholly owned IRF5 degrader KT-579, the Sanofi-partnered IRAK4 degrader KT-485 and the Gilead-licensed CDK2 molecular glue KT-200. Cash, equivalents and marketable securities were $1,645.9 million at September 30, 2026, with company-guided runway into 2029.

01 / Clinaptis view

The current read

Preliminary read: constructive on KT-621, cautious on the shares ahead of BROADEN2. The case for the asset is credible: an oral medicine that engages the pathway behind Dupixent, with near-complete STAT6 degradation in blood and skin and early clinical activity.

  1. What the evidence does not yet establish is how much of that activity survives a randomized, placebo-controlled, 16-week comparison. BroADen was small, open-label and four weeks long, so it supports mechanism and early activity but cannot size a placebo-adjusted effect, show durability or establish chronic safety.
  2. The shares already ask for a substantial commercial outcome, which means a positive trial is necessary but may not be sufficient: an effective drug is not automatically a differentiated one, and a differentiated drug is not automatically an attractive stock. A more favorable view would need a stronger benefit-risk profile than the central assumptions, credible support for a larger treated share, or a more attractive entry price.
  3. Valuation scenarios, readout thresholds and the supporting model are reserved for the forthcoming Clinaptis research note. No final rating or price target has been assigned.
02 / Consensus gap

Where the market may differ

The bullish read treats STAT6 degradation as an oral route to injectable-level efficacy in type 2 disease, with Dupixent's success as proof that the pathway pays. The cautious read separates pathway validation from asset validation: dupilumab works at the receptor, and intracellular STAT6 removal must show it reproduces that efficacy and a clean chronic safety profile in a controlled setting.

  1. Early dose-similar responses are consistent with pharmacological saturation but cannot, in 22 uncontrolled patients, settle the optimal dose or the size of a blinded effect. Convenience is a real commercial opening, but KT-621 also competes with oral JAK inhibitors, longer-acting injectables and other STAT6 agents.
  2. The disagreement is less about whether the mechanism is real than about how large the placebo-adjusted benefit is, whether it extends to deep clearance and itch relief, and how much of the resulting franchise is already in the price.
Coverage state
Standard profile
What the review turns on
Key variable

Size and consistency of the placebo-adjusted KT-621 effect in BROADEN2 across doses, read together with responder depth (EASI-75, clear or almost clear skin), itch relief and safety and discontinuations

Next catalyst

KT-621 · BROADEN2 Phase 2b atopic dermatitis results · by year-end 2026 (company guidance; no exact date disclosed)

03 / Pipeline

Key programs

4 assets · 5 programs

AssetIndicationStageNext event
KT-621
Atopic dermatitis
Phase 2b
Phase 2b results by year-end 2026. Watch the placebo-adjusted EASI effect at each dose, EASI-75 and clear-or-almost-clear responses, itch, safety and discontinuations. Eligible completers can enter a 52-week open-label extension; extension enrollment does not reveal blinded assignments or efficacy. First Phase 3 AD start is conditional on supportive data and FDA alignment (company guidance: by mid-2027)
Asthma
Phase 2b
Phase 2b results expected late 2027. A positive AD study would raise confidence in the molecule, but asthma requires its own evidence
KT-579
Lupus and other autoimmune disease
Phase 1 (healthy volunteers complete)
LUMORA Phase 1b, a placebo-controlled study of about 30 patients, planned to start by early 2027. Initiation is not efficacy evidence; healthy-volunteer data establish human proof of mechanism, not activity in lupus
KT-485
Immune-inflammatory disease
Phase 1
Sanofi-led development. Milestone and royalty rights provide economic exposure; contingent headline payments are not current cash
KT-200
Oncology
IND-enabling
Gilead-led IND-enabling work for a planned 2027 filing
04 / Connected research

Published on KYMR

View full archive
  1. 01

    Kymera and KT-621 in Atopic Dermatitis: BROADEN2 Can Clear Street’s Bar, but the Price Needs a Dupixent-Scale Franchise

    Can KT-621 deliver a dupilumab-like result in BROADEN2 for atopic dermatitis, and how much of that success does Kymera’s price already hold? Our dupilumab-like case is worth ~$102 a share, so what would the readout, and the franchise behind it, need to show to justify more?

    Read